We would like to thank Dr. Rizzo and Dr. Brandi for their constructive comments on
our study. We concur with their statement on the importance of conducting head-to-head
clinical trials that are sufficiently powered for the detection of clinically meaningful
outcomes. We agree that although our analysis showed a meaningful benefit to cardioprotective
therapies, it is not a substitute for such large prospective trials.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The role of cardioprotection in cancer therapy cardiotoxicity: JACC: CardioOncology state-of-the-art review.JACC: CardioOncology. 2022; 4: 19-37
- Long-term effectiveness of empiric cardio-protection in patients receiving cardiotoxic chemotherapies: a systematic review & bayesian network meta-analysis.Eur J Cancer. 2022; 169: 82-92
- Indices of effect existence and significance in the bayesian framework.Front Psychol. 2019; 10: 2767
- Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With Anthracyclines.JACC: Heart Failure. 2022;
- Hypertension and incident cardiovascular events following ibrutinib initiation.Blood. 2019; 134: 1919-1928
Article info
Publication history
Published online: July 21, 2022
Accepted:
June 20,
2022
Received:
June 16,
2022
Identification
Copyright
© 2022 Elsevier Ltd. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Long-term effectiveness of empiric cardio-protection in patients receiving cardiotoxic chemotherapies: A systematic review & bayesian network meta-analysisEuropean Journal of CancerVol. 169
- Letter re: “Long-term effectiveness of empiric cardio-protection in patients receiving cardiotoxic chemotherapies: A systematic review and Bayesian network meta-analysis”European Journal of CancerVol. 174
- PreviewThe cardiotoxicity of anticancer drugs represents a long-standing, important, and widely discussed issue in medical oncology [1]. We have witnessed impressive advances in cancer management over the last decade, with novel treatments reporting unprecedented response rates and improving clinical outcomes in several haematological and solid tumours [2]. Nonetheless, if on the one hand, new therapies have showed superior efficacy; on the other hand, these treatments have been associated with a non-negligible risk of increased cardiac toxicities.
- Full-Text
- Preview
